Clinical Trial Update: Study of Safety and Tolerability of DCR HBVS [Phase 1]

View source ↗

Summary

Phase 1 study of DCR HBVS in chronic hepatitis B has completed, with safety and tolerability data reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• DCR HBVS

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Hepatitis B, Chronic | Phase 1 | Status: COMPLETED